ClinicalTrials.Veeva

Menu

Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients

U

University Hospital, Angers

Status and phase

Terminated
Phase 4

Conditions

Alcoholic Cirrhosis

Treatments

Drug: Propranolol - Spironolactone

Study type

Interventional

Funder types

Other

Identifiers

NCT00188045
PHRC 01-13

Details and patient eligibility

About

The aim of this study was assesment of splanchnic and systemic hemodynamic effects of chronic administration (2 month) of spironolactone or propranolol, alone or in association in alcoholic cirrhotic patients. The patients were randomized in 4 groups (aldactone 150 mg/day, propranolol 160 mg/day, aldactone 150 mg/day + propranolol 160 mg/day, placebo). Systemic and splanchnic hemodynamic effect were evaluated by hepatic venous pressure gradient measurements before and after 2 month of treatment.

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Indication of transjugular hepatic biopsy
  • alcoholic cirrhosis
  • presence of oesophageal varices ≤ stade 2

Exclusion criteria

  • renal insufficiency
  • natremia ≤ 135 mmol/l
  • vasoactive treatment in the last month before inclusion
  • hepatocellular carcinoma
  • positive HIV and HCV patients
  • paracentesis in the last week before inclusion
  • digestive bleeding in one last week
  • oesophageal varices stade 3 or 2 with red signs

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems